Novel antibody frameworks

Abstract

The present invention relates to novel antibody frameworks with advantageous properties.

1 - 17 . (canceled) 
     
     
         18 . The isolated antibody or functional fragment thereof of  claim 21 , which is selected from the group consisting of: an IgG antibody, a Fab fragment, an scFv fragment, a single-chain diabody, a tandem single-chain diabody, a linear dimeric single-chain diabody, a circular dimeric single-chain diabody, a bispecific T-cell engager, a tandem tri-scFv, a tribody, a triabody, a bispecific Fab2, a di-miniantibody, a tetrabody, an scFv-Fc-scFv fusion, a di-diabody, a DVD-Ig, an IgG-scFab, an scFab-dsscFv, an Fv2-Fc, an IgG-scFv fusion, a bsAb with an scFv linked to the C-terminus of the light chain of an IgG, a Bs1Ab with an scFv linked to the N-terminus of the light chain of an IgG, a Bs2Ab with an scFv linked to N-terminus of the heavy chain of an IgG, a Bs3Ab with an scFv linked to the C-terminus of the heavy chain of an IgG, a Ts1Ab with an scFv linked to the N-terminus of both the heavy chain and the light chain of an IgG, a Ts2Ab with a dsscFv linked to the C-terminus of the heavy chain of an IgG, a Knobs-into-Holes bispecific IgG and a DuoBody bispecific IgG. 
     
     
         19 . A pharmaceutical composition comprising the isolated antibody or functional fragment thereof of  claim 21 , and optionally a pharmaceutically acceptable carrier and/or excipient. 
     
     
         20 . A method for producing the isolated antibody or functional fragment thereof according to  claim 21 , comprising the step of expressing a nucleic acid sequence or a collection of nucleic acid sequences encoding said isolated antibody or functional fragment according to  claim 21  or a vector or collection of vectors comprising said nucleic acid sequence or said collection of nucleic acid sequences optionally in a host cell. 
     
     
         21 . An isolated antibody or functional fragment thereof comprising (a) a human VH domain comprising framework regions I to III belonging to a human VH domain subfamily selected from the group consisting of VH1A according to SEQ ID NO: 27, VH1B according to SEQ ID NO: 28, VH2 according to SEQ ID NO: 29, VH3 according to SEQ ID NO: 30, VH4 according to SEQ ID NO: 31, VH5 according to SEQ ID NO: 32, and VH6 according to SEQ ID NO: 33, further comprising a human framework region IV, and (b) a VL domain comprising (i) human Vκ framework regions I to III, wherein said Vκ framework regions I to III belong to a Vκ domain subfamily selected from the group consisting of Vκ1 according to SEQ ID NO: 23, Vκ2 according to SEQ ID NO: 24, Vκ3 according to SEQ ID NO: 25, and Vκ4 according to SEQ ID NO: 26; (ii) VL rabbit or rodent CDR domains CDR1, CDR2 and CDR3; and (iii) a framework region IV, which has one or two mutations compared to the closest human Vλ germ line sequence for framework region IV selected from the group of sequences consisting of SEQ ID NOs: 16 to 22. 
     
     
         22 . The isolated antibody or functional fragment thereof of  claim 21 , wherein said framework region IV has one mutation compared to the closest human Vλ germ line sequence for framework region IV selected from the group of sequences consisting of SEQ ID NOs: 16 to 22.